{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:47Z","timestamp":1761093047437,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.urolonc.2010.02.007","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T06:48:06Z","timestamp":1284706086000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations"],"prefix":"10.1016","volume":"30","author":[{"given":"Davor","family":"Librenjak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijan","family":"\u0160itum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vrdoljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimir","family":"Milosti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip","family":"Gotovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2010.02.007_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0094-0143(05)70229-9","article-title":"The natural history of bladder cancer","volume":"27","author":"Lee","year":"2000","journal-title":"Urol Clin North Am"},{"year":"2002","series-title":"TNM Classification of Malignant Tumors","author":"Sobin","key":"10.1016\/j.urolonc.2010.02.007_bib2"},{"key":"10.1016\/j.urolonc.2010.02.007_bib3","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","article-title":"Superficial bladder cancer: Progression and recurrence","volume":"130","author":"Heney","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0094-0143(21)00421-3","article-title":"Immunotherapy for superficial bladder cancer","volume":"19","author":"Morales","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2010.02.007_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0094-0143(21)00422-5","article-title":"Bacillus Calmette-Guerin immunotherapy","volume":"19","author":"Brosman","year":"1992","journal-title":"Urol Clin North Am"},{"year":"2000","series-title":"Intravesical immunotherapy with bacillus Calmette-Guerin","author":"Bohle","key":"10.1016\/j.urolonc.2010.02.007_bib7"},{"key":"10.1016\/j.urolonc.2010.02.007_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"Bacillus Calmette-Guerin vs. doxorubicin vs. thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer","volume":"142","author":"Martinez-Pineiro","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib9","first-page":"187","article-title":"Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer","volume":"44","author":"Librenjak","year":"2003","journal-title":"CMJ"},{"year":"1993","series-title":"Histologic typing of urinary bladder tumors","author":"Mostofi","key":"10.1016\/j.urolonc.2010.02.007_bib10"},{"key":"10.1016\/j.urolonc.2010.02.007_bib11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0022-5347(17)49104-X","article-title":"The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin","volume":"133","author":"De Kernion","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0022-5347(17)39546-0","article-title":"Long-term follow-up of patients treated with one or two 6-week courses of intravesical bacillus Calmette-Guerin: Analysis of possible predictors of response free tumor","volume":"144","author":"Coplen","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-5347(17)38865-1","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"142","author":"Sarosdy","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib15","series-title":"Optimal therapy for patients with high-risk superficial bladder cancer-controversy and consensus","first-page":"103","article-title":"Towards the optimal BCG regimen: Comparison of maintenance schedules","author":"Lamm","year":"1997"},{"key":"10.1016\/j.urolonc.2010.02.007_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"BCG immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"156","author":"Lunholm","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib20","first-page":"164","article-title":"Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis factors affecting tumor progression","volume":"73","author":"Herr","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year follow-up","volume":"147","author":"Herr","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-Year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib24","first-page":"47","article-title":"Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.urolonc.2010.02.007_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: Progression-free and disease specific survival with minimum 10-year follow-up","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000052376","article-title":"Preventing progression and improving survival with BCG maintenance","volume":"37","author":"Lamm","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib27","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with urothelial carcinoma: A cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib28","first-page":"1717","article-title":"Predicting prognosis in patients with superficial bladder cancer","volume":"12","author":"De Vere","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.urolonc.2010.02.007_bib29","series-title":"Optimal therapy for patients with high-risk superficial bladder cancer-controversy and consensus","first-page":"55","article-title":"Therapy for the T1G3 bladder carcinoma","author":"Otto","year":"1997"},{"key":"10.1016\/j.urolonc.2010.02.007_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin vs. chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2010.02.007_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143910000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:58:07Z","timestamp":1761040687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143910000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1078143910000487"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.02.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2010.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}